EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An Overview of Endometrial Cancer with Novel Therapeutic Strategies

Theresa M Kuhn, Saeeda Dhanani, Sarfraz Ahmad iD

Current Oncology · 27.08.2023 · 30 (9) · 7904-7919

DOI: 10.3390/curroncol30090574 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 27.08.2023. Verfasst von Theresa M Kuhn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Endometrial Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) stands as the most prevalent gynecologic malignancy. In the past, it was classified based on its hormone sensitivity. However, The Cancer Genome Atlas has categorized EC into four groups, which offers a more objective and reproducible classification and has been shown to have prognostic and therapeutic implications. Hormonally driven EC arises from a precursor lesion known as endometrial hyperplasia, resulting from unopposed estrogen. EC is usually diagnosed through biopsy, followed by surgical staging unless advanced disease is expected. The typical staging consists of a hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsies, with a preference placed on a minimally invasive approach. The stage of the disease is the most significant prognostic marker. However, factors such as age, histology, grade, myometrial invasion, lymphovascular space invasion, tumor size, peritoneal cytology, hormone receptor status, ploidy and markers, body mass index, and the therapy received all contribute to the prognosis. Treatment is tailored based on the stage and the risk of recurrence. Radiotherapy is primarily used in the early stages, and chemotherapy can be added if high-grade histology or advanced-stage disease is present. The risk of EC recurrence increases with advances in stage. Among the recurrences, vaginal cases exhibit the most favorable response to treatment, typically for radiotherapy. Conversely, the treatment of widespread recurrence is currently palliative and is best managed with chemotherapy or hormonal agents. Most recently, immunotherapy has emerged as a promising treatment for advanced and recurrent EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalEndometrial NeoplasmsFemaleHumansImmunotherapyBiopsy

Stichwörter der Autor:innen

diagnosisendometrial cancerhyperplasiaprognosistreatment

Autor:innen und Institutionen

  • Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.
  • Philadelphia College of Osteopathic Medicine, Suwanee, GA 30024, USA.

ORCID-Profile: Sarfraz Ahmad

Zitieren

APA

Kuhn, T. M., Dhanani, S., & Ahmad, S. (2023). An Overview of Endometrial Cancer with Novel Therapeutic Strategies. Current Oncology, 30(9), 7904-7919. https://doi.org/10.3390/curroncol30090574

Vancouver

Kuhn TM, Dhanani S, Ahmad S. An Overview of Endometrial Cancer with Novel Therapeutic Strategies. Current Oncology. 2023;30(9):7904-7919. doi:10.3390/curroncol30090574

BibTeX
@article{Kuhn2023,
  author = {Kuhn, Theresa M and Dhanani, Saeeda and Ahmad, Sarfraz},
  title = {An Overview of Endometrial Cancer with Novel Therapeutic Strategies},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {9},
  pages = {7904--7919},
  doi = {10.3390/curroncol30090574}
}
Kostenlos starten →